{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:35:10Z","timestamp":1767926110579,"version":"3.49.0"},"reference-count":49,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0035_s_001_w2aab3b7c11b1b6b1aab1c14b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A new treatment using bidirectional intraperitoneal (IP) and intravenous (IV) chemotherapy developed by Asiatic surgeons improves outcomes in patients with synchronous peritoneal metastasis (PM) from gastric cancer (GC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0035_s_002_w2aab3b7c11b1b6b1aab1c14b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We enrolled six consecutive patients with unresectable PM from GC who underwent bidirectional chemotherapy using IP docetaxel and IV FOLFOX or LV5FU2. In one course, IP docetaxel 30\u2006mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      was administrated on days 1, 8 and 15, and IV FOLFOX or LV5FU2 was administered on days 1 and 15, followed by 7\u2006days of rest. Before and after a complete bidirectional cycle of three courses, the peritoneal cancer index (PCI) was evaluated by laparoscopy. The primary endpoint was to evaluate the feasibility and safety of bidirectional chemotherapy. Secondary endpoints were overall survival (OS), and the success of the therapeutic strategy was reflected by a decrease of 25% of the initial PCI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0035_s_003_w2aab3b7c11b1b6b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients completed one bidirectional cycle. The regimen was well tolerated. The median OS was 13\u2006months [range 5\u201318], and the 1-year OS rate was 67%. After the first bidirectional cycle, the PCI decrease \u226525% of the initial value in four patients. A major histological response was observed in four patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0035_s_004_w2aab3b7c11b1b6b1aab1c14b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first Western study and confirms the feasibility and safety of bidirectional treatment using IP and IV chemotherapy for patients with unresectable PM from GC, resulting in a 13-month median OS with limited morbidity. The decrease in PCI after one bidirectional cycle is promising.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0035","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T11:49:11Z","timestamp":1590493751000},"source":"Crossref","is-referenced-by-count":5,"title":["Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries"],"prefix":"10.1515","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1231-5240","authenticated-orcid":false,"given":"Rea","family":"Lo Dico","sequence":"first","affiliation":[{"name":"University of Paris, UMR 1275 CAP Paris-Tech, Department of Digestive Surgery , Lariboisi\u00e8re Hospital, AP-HP , F-75010 Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marc","family":"Gornet","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Gastroenterology and Digestive Oncology , Saint-Louis Hospital, AP-HP , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Guglielmo","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery , Lariboisiere Hospital, AP-HP , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Gastroenterology and Digestive Oncology , Georges Pompiodou European Hospital, AP-HP , Paris, University of Paris , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Gastroenterology and Digestive Oncology , Georges Pompiodou European Hospital, AP-HP , Paris, University of Paris , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[{"name":"University of Paris, UMR 1275 CAP Paris-Tech, Department of Digestive Surgery , Lariboisi\u00e8re Hospital, AP-HP , F-75010 Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"2025120909253175342_j_pp-2019-0035_ref_001_w2aab3b7c11b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010:CD004064. DOI:10.1002\/14651858.CD004064.pub3.","DOI":"10.1002\/14651858.CD004064.pub3"},{"key":"2025120909253175342_j_pp-2019-0035_ref_002_w2aab3b7c11b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 2014;134:622\u20138.","DOI":"10.1002\/ijc.28373"},{"key":"2025120909253175342_j_pp-2019-0035_ref_003_w2aab3b7c11b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol 2016;17:1697\u2013708.","DOI":"10.1016\/S1470-2045(16)30531-9"},{"key":"2025120909253175342_j_pp-2019-0035_ref_004_w2aab3b7c11b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Wilke H, Muro K, van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224\u201335.","DOI":"10.1016\/S1470-2045(14)70420-6"},{"key":"2025120909253175342_j_pp-2019-0035_ref_005_w2aab3b7c11b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 2017;3:1237\u201344.","DOI":"10.1001\/jamaoncol.2017.0515"},{"key":"2025120909253175342_j_pp-2019-0035_ref_006_w2aab3b7c11b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219\u201328.","DOI":"10.1016\/S1470-2045(04)01425-1"},{"key":"2025120909253175342_j_pp-2019-0035_ref_007_w2aab3b7c11b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34\u201343.","DOI":"10.1056\/NEJMoa052985"},{"key":"2025120909253175342_j_pp-2019-0035_ref_008_w2aab3b7c11b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20\u20136.","DOI":"10.1001\/archsurg.139.1.20"},{"key":"2025120909253175342_j_pp-2019-0035_ref_009_w2aab3b7c11b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Fujimura T, Nishimura G, Falla R, Sawa T, Katayama K, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437\u201344.","DOI":"10.1016\/S0039-6060(96)80145-0"},{"key":"2025120909253175342_j_pp-2019-0035_ref_010_w2aab3b7c11b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol 2006;32:661\u20135.","DOI":"10.1016\/j.ejso.2006.03.007"},{"key":"2025120909253175342_j_pp-2019-0035_ref_011_w2aab3b7c11b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol 2009;100:311\u20136.","DOI":"10.1002\/jso.21324"},{"key":"2025120909253175342_j_pp-2019-0035_ref_012_w2aab3b7c11b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol 2018;36:1922\u20139.","DOI":"10.1200\/JCO.2018.77.8613"},{"key":"2025120909253175342_j_pp-2019-0035_ref_013_w2aab3b7c11b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Yonemura M, Katsumata N, Hashimoto H, Satake S, Kaneko M, Kobayashi Y, et al. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. Jpn J Clin Oncol 2009;39:443\u20138.","DOI":"10.1093\/jjco\/hyp036"},{"key":"2025120909253175342_j_pp-2019-0035_ref_014_w2aab3b7c11b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010;21:67\u201370.","DOI":"10.1093\/annonc\/mdp260"},{"key":"2025120909253175342_j_pp-2019-0035_ref_015_w2aab3b7c11b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Imano M, Imamoto H, Itoh T, Satou T, Peng YF, Yasuda A, et al. Impact of intraperitoneal chemotherapy after gastrectomy with positive cytological findings in peritoneal washings. Eur Surg Res 2011;47:254\u20139.","DOI":"10.1159\/000333803"},{"key":"2025120909253175342_j_pp-2019-0035_ref_016_w2aab3b7c11b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol 2012;105:38\u201342.","DOI":"10.1002\/jso.22057"},{"key":"2025120909253175342_j_pp-2019-0035_ref_017_w2aab3b7c11b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2013;71:1265\u201372.","DOI":"10.1007\/s00280-013-2122-0"},{"key":"2025120909253175342_j_pp-2019-0035_ref_018_w2aab3b7c11b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 2013;119:3354\u20138.","DOI":"10.1002\/cncr.28204"},{"key":"2025120909253175342_j_pp-2019-0035_ref_019_w2aab3b7c11b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol 2014;21:1147\u201352.","DOI":"10.1245\/s10434-013-3443-2"},{"key":"2025120909253175342_j_pp-2019-0035_ref_020_w2aab3b7c11b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Kim YW, Joo J, Yoon HM, Eom BW, Ryu KW, Choi IJ, et al. Different survival outcomes after curative R0-resection for Eastern Asian and European gastric cancer: results from a propensity score matched analysis comparing a Korean and a German specialized center. Medicine (Baltimore) 2016;95:e4261.","DOI":"10.1097\/MD.0000000000004261"},{"key":"2025120909253175342_j_pp-2019-0035_ref_021_w2aab3b7c11b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Evers DJ, Verwaal VJ. Indication for oophorectomy during cytoreduction for intraperitoneal metastatic spread of colorectal or appendiceal origin. Br J Surg 2011;98:287\u201392.","DOI":"10.1002\/bjs.7303"},{"key":"2025120909253175342_j_pp-2019-0035_ref_022_w2aab3b7c11b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Najah H, Lo Dico R, Grienay M, Dohan A, Dray X, Pocard M. Single-incision flexible endoscopy (SIFE) for detection and staging of peritoneal carcinomatosis. Surg Endosc 2016;30:3808\u201315.","DOI":"10.1007\/s00464-015-4682-z"},{"key":"2025120909253175342_j_pp-2019-0035_ref_023_w2aab3b7c11b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u201374.","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2025120909253175342_j_pp-2019-0035_ref_024_w2aab3b7c11b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Kushnir CL, Fleury AC, Silver DF, Spirtos NM. Intraperitoneal catheter placement: the \u201cHammock\u201d technique. Clin Ovarian Other Gynecologic Cancer 2012;5:24\u20136.","DOI":"10.1016\/j.cloc.2011.08.001"},{"key":"2025120909253175342_j_pp-2019-0035_ref_025_w2aab3b7c11b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176\u201381.","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"2025120909253175342_j_pp-2019-0035_ref_026_w2aab3b7c11b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer 2009;45:3017\u201326.","DOI":"10.1016\/j.ejca.2009.08.014"},{"key":"2025120909253175342_j_pp-2019-0035_ref_027_w2aab3b7c11b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol 2011;22:2179\u201390.","DOI":"10.1093\/annonc\/mdq721"},{"key":"2025120909253175342_j_pp-2019-0035_ref_028_w2aab3b7c11b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205\u201313.","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"2025120909253175342_j_pp-2019-0035_ref_029_w2aab3b7c11b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358\u201363.","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"2025120909253175342_j_pp-2019-0035_ref_030_w2aab3b7c11b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32:3520\u20136.","DOI":"10.1200\/JCO.2013.54.1011"},{"key":"2025120909253175342_j_pp-2019-0035_ref_031_w2aab3b7c11b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Bang YJ, van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687\u201397.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2025120909253175342_j_pp-2019-0035_ref_032_w2aab3b7c11b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res 2017. DOI:10.1158\/1078-0432.CCR-16-2211.","DOI":"10.1158\/1078-0432.CCR-16-2211"},{"key":"2025120909253175342_j_pp-2019-0035_ref_033_w2aab3b7c11b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11\u201320.","DOI":"10.1056\/NEJMoa055531"},{"key":"2025120909253175342_j_pp-2019-0035_ref_034_w2aab3b7c11b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715\u201321.","DOI":"10.1200\/JCO.2010.33.0597"},{"key":"2025120909253175342_j_pp-2019-0035_ref_035_w2aab3b7c11b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol 2010;36:1131\u20138.","DOI":"10.1016\/j.ejso.2010.09.006"},{"key":"2025120909253175342_j_pp-2019-0035_ref_036_w2aab3b7c11b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370\u20137.","DOI":"10.1245\/s10434-010-1039-7"},{"key":"2025120909253175342_j_pp-2019-0035_ref_037_w2aab3b7c11b1b6b1ab2b2c37Aa","doi-asserted-by":"crossref","unstructured":"Karanicolas PJ, Metrakos P, Chan K, Asmis T, Chen E, Kingham TP, et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol 2014;21:e129\u201336.","DOI":"10.3747\/co.21.1577"},{"key":"2025120909253175342_j_pp-2019-0035_ref_038_w2aab3b7c11b1b6b1ab2b2c38Aa","doi-asserted-by":"crossref","unstructured":"Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009;27:3465\u201371.","DOI":"10.1200\/JCO.2008.20.1301"},{"key":"2025120909253175342_j_pp-2019-0035_ref_039_w2aab3b7c11b1b6b1ab2b2c39Aa","doi-asserted-by":"crossref","unstructured":"Sgarbura O, Samalin E, Carrere S, Mazard T, de Forges H, Alline M, et al. Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study. Pleura Peritoneum 2016;1:209\u201315.","DOI":"10.1515\/pp-2016-0018"},{"key":"2025120909253175342_j_pp-2019-0035_ref_040_w2aab3b7c11b1b6b1ab2b2c40Aa","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT, Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treat Rep 1978;62:1\u201311."},{"key":"2025120909253175342_j_pp-2019-0035_ref_041_w2aab3b7c11b1b6b1ab2b2c41Aa","doi-asserted-by":"crossref","unstructured":"Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583\u201392.","DOI":"10.1038\/nrc1893"},{"key":"2025120909253175342_j_pp-2019-0035_ref_042_w2aab3b7c11b1b6b1ab2b2c42Aa","doi-asserted-by":"crossref","unstructured":"Wang ZB, Li M, Li JC. Recent advances in the research of lymphatic stomata. Anat Rec (Hoboken) 2010;293:754\u201361.","DOI":"10.1002\/ar.21101"},{"key":"2025120909253175342_j_pp-2019-0035_ref_043_w2aab3b7c11b1b6b1ab2b2c43Aa","unstructured":"Morgan RJ, Jr., Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics Clin Cancer Res 2003;9:5896\u2013901."},{"key":"2025120909253175342_j_pp-2019-0035_ref_044_w2aab3b7c11b1b6b1ab2b2c44Aa","unstructured":"Fujiwara Y, Nishida T, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, et al. Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination. Anticancer Res 2010;30:1335\u20139."},{"key":"2025120909253175342_j_pp-2019-0035_ref_045_w2aab3b7c11b1b6b1ab2b2c45Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2010;2:85\u201397.","DOI":"10.4251\/wjgo.v2.i2.85"},{"key":"2025120909253175342_j_pp-2019-0035_ref_046_w2aab3b7c11b1b6b1ab2b2c46Aa","doi-asserted-by":"crossref","unstructured":"Fava BE, da Costa WL, Jr., Medeiros ML, Sonagli M, de Castro Ribeiro HS, Diniz AL, et al. Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center. World J Surg Oncol 2018;16:62.","DOI":"10.1186\/s12957-018-1363-0"},{"key":"2025120909253175342_j_pp-2019-0035_ref_047_w2aab3b7c11b1b6b1ab2b2c47Aa","doi-asserted-by":"crossref","unstructured":"Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol 2006;32:625\u20137.","DOI":"10.1016\/j.ejso.2006.03.015"},{"key":"2025120909253175342_j_pp-2019-0035_ref_048_w2aab3b7c11b1b6b1ab2b2c48Aa","doi-asserted-by":"crossref","unstructured":"Garg PK, Jara M, Alberto M, Rau B. The role of pressurized intraperitoneal aerosol chemotherapy in the management of gastric cancer: a systematic review. Pleura Peritoneum 2019;4:20180127.","DOI":"10.1515\/pp-2018-0127"},{"key":"2025120909253175342_j_pp-2019-0035_ref_049_w2aab3b7c11b1b6b1ab2b2c49Aa","doi-asserted-by":"crossref","unstructured":"Girshally R, Demtroder C, Albayrak N, Zieren J, Tempfer C, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2016;14:253.","DOI":"10.1186\/s12957-016-1008-0"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/5\/2\/article-20190035.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0035\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0035\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:04:19Z","timestamp":1765278259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0035\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,5,15]]},"published-print":{"date-parts":[[2020,5,26]]}},"alternative-id":["10.1515\/pp-2019-0035"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0035","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"article-number":"20190035"}}